Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

[2] This drug was developed by Genentech/Roche.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.